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Germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene were recently identified in individuals with pituitary
adenoma predisposition (PAP). These patients have prolactin (PRL) or growth hormone (GH) oversecreting pituitary adenomas, the
latter exhibiting acromegaly or gigantism. Loss-of-heterozygosity (LOH) analysis revealed that AIP is lost in PAP tumours, suggesting
that it acts as a tumour-suppressor gene. Aryl hydrocarbon receptor interacting protein is involved in several pathways, but it is best
characterised as a cytoplasmic partner of the aryl hydrocarbon receptor (AHR). To examine the possible role of AIP in the genesis of
common cancers, we performed somatic mutation screening in a series of 373 colorectal cancers (CRCs), 82 breast cancers, and 44
prostate tumour samples. A missense R16H (47G4A) change was identified in two CRC samples, as well as in the respective normal
tissues, but was absent in 209 healthy controls. The remaining findings were silent, previously unreported, changes of the coding, non-
coding, or untranslated regions of AIP. These results suggest that somatic AIP mutations are not common in CRC, breast, and prostate
cancers.
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Germline mutations of aryl hydrocarbon receptor interacting
protein (AIP), a gene coding for a cytoplasmic interaction partner
of aryl hydrocarbon receptor (AHR) (also known as dioxin
receptor), were recently described to cause low-penetrance
pituitary adenoma predisposition (PAP) (Vierimaa et al, 2006).
Pituitary adenomas are common benign neoplasms of the
anterior pituitary gland and account for approximately 15% of
intracranial tumours. About two-thirds oversecrete pituitary
hormones, among which growth hormone (GH) and prolactin
(PRL)-oversecreting adenomas are the most common (Heaney and
Melmed, 2004). The causal effect of GH oversecretion is
acromegaly or gigantism. Cardiovascular, cerebrovascular, respira-
tory, and metabolic diseases are potential more severe conse-
quences (Melmed et al, 1995; Colao et al, 2004; Jenkins, 2004).
There is accumulating evidence for an increased risk of colorectal
cancer (CRC) in acromegaly patients, but also circumstantial
evidence that breast and prostate malignancies may arise at a higher
risk in the context of acromegaly (Jenkins, 2004). An attractive
explanation for the increased risk of CRC in acromegaly has been the
link to insulin-like growth factor I (IGF-I). Plasma GH triggers the
production of IGF-I from the liver, which in turn stimulates the
growth of organs and tissues, through its known mitogenic and
antiapoptotic properties. Any imbalance in the tight control between
epithelial cell turn-over and cell death may result in epithelial
hyperproliferation, promoting the formation of hyperplastic polyps
and colorectal adenomas (Jenkins et al,2 0 0 6 ) .C h a net al (1998) have
reported a strong positive association between IGF-I levels and
increased prostatic malignancy , whereas Peyrat et al (1993) have
described increased IGF-I levels in primary breast cancers.
We recently described the PAP phenotype in pituitary adenoma
patients from Northern Finland (Vierimaa et al, 2006). Germline
AIP mutations segregated with the PAP phenotype in the familial
cases, and germline mutations were also identified in sporadic
acromegaly patients from Northern Finland. Loss-of-heterozygo-
sity (LOH) analysis revealed loss of wild-type allele in all tumour
samples available, suggesting that AIP is likely to act as a tumour
suppressor gene.
Aryl hydrocarbon receptor interacting protein is best charac-
terised through its cytoplasmic interaction with the AHR (Carver
and Bradfield, 1997), a transcription factor that regulates many
xenobiotic metabolising enzymes (Meyer and Perdew, 1999;
Marlowe and Puga, 2005). Aryl hydrocarbon receptor interacting
protein modulates the stability and subcellular localisation of AHR
by preventing its dynamic nucleocytoplasmic shuttling (Pollenz
and Dougherty, 2005). Aryl hydrocarbon receptor interacting
protein has also been reported to interact with phospho diesterase
4A5 (PDE4A5) (Bolger et al, 2003) and peroxisome proliferator-
activated receptor-a (PPAR-a) (Sumanasekera et al, 2003).
Many genes involved in hereditary cancer syndromes are also
somatically mutated in tumours that are not prominently
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sassociated with the respective syndromes (Li et al, 1997; Avizienyte
et al, 1999; Ali et al, 1999; Sanchez-Cespedes et al, 2002). The
identification of AIP as a candidate tumour-suppressor gene, lost
in both GH and PRL-secreting pituitary adenomas, prompted us to
study its possible involvement in other tumour types. According to
the global cancer statistics reviewed by Parkin et al for the year
2002, breast (18%), colorectal (12%), and prostate cancers (10%)
are, in terms of prevalence, the most common worldwide (Parkin
et al, 2005). To characterise the possible contribution of somatic
AIP mutations to the genesis of common cancers, we performed a
mutation analysis in a series of CRC, breast, and prostate cancer
samples. The inclusion of breast cancer samples was also based on
a recent report from Eltom et al (2006), that the levels of nuclear
AHR – the cytoplasmic interaction partner of AIP – were
dramatically elevated in human breast carcinomas of advanced
malignancy compared to earlier stages of tumour progression. In
the tumours of advanced malignancy, the nuclear AHR was
stabilised and constitutively active.
MATERIALS AND METHODS
Sample material
The study was approved by the appropriate ethics review
committees. Deoxyribonucleic acid from 52 CRC samples (44
microsatellite stable (MSS) and eight microsatellite unstable (MSI),
chosen from a series collected between 1994–1998; Aaltonen et al,
1998; Salovaara et al, 2000) were used for AIP mutation analysis.
Aryl hydrocarbon receptor interacting protein exon 1 screening was
subsequently extended to 321 CRC samples (272 MSS and 49 MSI)
also chosen from the same series collected between 1994 and 1998.
The whole set of 373 CRC patients had a mean age at diagnosis of
68 years (range 30–88 years). Colorectal cancer samples were
collected as fresh-frozen tissue specimens and displayed at least
50% tumour tissue, according to pathologist’s histological evalua-
tion. Corresponding normal tissue DNA was extracted from blood
or normal colonic epithelium, distant from the tumour margins.
A total of 82 breast cancer DNA samples were available for the
study. The samples were derived regardless of family history, from
patients diagnosed between 1988 and 1994 at the Oulu University
Hospital (Winqvist et al, 1995). Complete AIP screening was
initially performed in 43 samples. Subsequently, AIP exon 6
screening was extended to 39 additional tumour samples. The 82
individuals had a mean age at diagnosis of 54 years (range 29–87
years).
In addition, 44 unselected, genome Phi-amplified (GenomiPhi
Amplification kit, Amersham, GE Healthcare, UK), prostate
tumour samples from the Tampere region (Waltering et al, 2006)
were analysed. Of these, 28 were previously untreated cancers
(primary), 12 were hormone-refractory, and four were charac-
terised as benign prostate hyperplasia. The individuals had a mean
age at diagnosis of 66 years (range 56–87 years). DNA from 209
anonymous, cancer-free Finnish Red Cross blood donors served as
a population-matched control material.
Mutation screening
The coding region, exon–intron boundaries, as well as the 50 and 30
untranslated regions (UTRs) of AIP were PCR-amplified and
sequenced as previously described by Vierimaa et al (2006). The
potential splicing effect of an intronic change in one breast tumour
sample was predicted by computational methods using NetGene2
(http://www.cbs.dtu.dk/services/NetGene2) and the Berkley Droso-
phila Genome Project (BDGP) (http://www.fruitfly.org/seq_tools/
splice.html) splice site prediction programs. The protein sequences
of human AIP and its homologues in other species were obtained
from the University of California in Santa Cruz (UCSC) Genome
Bioinformatics database, version March 2006 (http://genome.ucsc.
edu), and Ensembl Genome Browser, version 38–April 2006 (http://
www.ensembl.org).
RESULTS
Among the 52 CRC samples initially screened, a heterozygous
missense change, R16H (47G4A) in exon 1 was detected in two
samples, one being MSS and the other MSI (Table 1). Sequencing
of the corresponding normal tissues showed the presence of R16H
in the germline in both cases (Figure 1). The change was absent in
209 healthy controls. The MSS patient had been diagnosed with
cancer of the rectum at the age of 64 years. Owing to unilateral
breast enlargement, the patient had been examined by nuclear
magnetic resonance (NMR) for pituitary adenoma. However,
owing to restricted access to medical records in the private sector,
and given that this patient is now deceased, no detailed data were
available. The MSI patient had been diagnosed with cancer of the
colon at the age of 81 years. Her sister had been also diagnosed
with CRC at the age of 78 years, and her daughter with cervical
cancer at the age of 33 years. Interestingly, her brother had been
diagnosed with carcinoid tumour of the rectum at the age of 66
years.
Not knowing whether R16H is a very rare polymorphism or a
pathogenic mutation related to colorectal cancer, we extended the
screening of exon 1 to an additional series of 321 CRC samples, but
no additional R16H carriers were observed. In one of these
samples, we found a heterozygous G4C change in the 50 UTR, 5bp
upstream of the start codon (Table 1). This patient had been
diagnosed with cancer of the rectum at the age of 72 years. The
Table 1 AIP changes identified in colorectal, breast, and prostate tumour samples
Cancer type
Number of
patients with
a variant Location Nucleotide change
Amino-acid
change
Individuals (allele
frequencies)
Controls (allele
frequencies)
Colorectal 2 Exon 1 47G4A R16H 2/373 (0.27%) 0/209
6 Exon 1 68G4A G23E 6/373 (0.8%) 5/209 (1.2%)
15 0 UTR  5G4C — 1/373 (0.13%) 0/209
23 0 UTR +60G4C (heterozygous) — 2/373 (0.27%) 3/182 (0.8%)
Breast 1 Intron 3 IVS3+15C4T — 1/43 (1.16%) NA
53 0 UTR +60G4C (heterozygous) —
1 +60G4C (homozygous) — 6/81 (4.3%) 3/182 (0.8%)
Prostate 1 Exon 1 36G4A G12G 1/44 (1.14%) 0/209
1 Exon 5 714C4T C238C 1/44 (1.14%) NA
NA¼not analysed; UTR¼untranslated region.
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healthy controls.
A second heterozygous missense change in exon 1, G23E
(68G4A), was identified in six out of the total of 373 (0.8%) CRC
samples. This change was also observed in five out of 209 healthy
controls (1.2%) (Table 1). Finally, a previously unreported
heterozygous G4C variant of the 30 UTR, 60bp downstream of
the termination codon, was identified in two MSI samples out of
the total of 373 CRC tumours (0.3%). The variant was also
observed in three out of 182 (0.8%) healthy controls in
heterozygous form.
The screening of breast tumour samples also revealed the G4C
change in the 30 UTR, 60bp downstream of the termination codon.
The change was present in six out of 81 (4.3%) breast tumours, of
which five were heterozygotes and one was homozygote for the
rare C allele (Table 1). The variant was also observed in three out
of 182 (0.8%) healthy controls in heterozygous form (P¼0.026,
Fisher’s exact test). In addition, one breast tumour sample had a
heterozygous change at IVS3þ15C4T (Table 1). This change was
not predicted to have a splicing effect, as tested in silico by
NetGene2 and BDGP programs.
In prostate tumour samples, the only observed AIP alterations
were two previously unreported variants, likely to be silent
polymorphisms, in one sample each (Table 1): G12G (36G4A)
coding for glycine in exon 1 in a primary cancer sample and C238C
(714C4T) coding for cystein in exon 5 in a hormone-refractory
cancer sample. AIP mutation screening results are summarised in
Table 1.
DISCUSSION
Recently, we reported that AIP is a low-penetrance tumour
susceptibility gene, conferring genetic predisposition to pituitary
adenomas with high relative, but low absolute, risk (Vierimaa et al,
2006). Little is known concerning the involvement of AIP in
pituitary tumorigenesis or progression, as its functional role in
that context remains to be clarified. Here, we wished to examine
whether AIP is somatically mutated in the most common cancer
types: Colorectal, breast, and prostate cancer. No somatic AIP
mutations were detected in this study, in accordance with a recent
study by Sjo ¨blom et al (2006); AIP was not found to be mutated in
human breast and CRC cancer.
The presence of the missense change R16H in the tumour and
corresponding normal tissue (Figure 1) of two CRC patients is an
interesting finding. First, the fact that arginine at AIP codon 16 is a
highly conserved amino acid among species (Figure 2), second,
from the possibility that an occult pituitary adenoma had been
present in the MSS patient in which R16H was identified, one
could speculate that such an occult PRL and GH-secreting
adenoma may have promoted the breast enlargement, as well as
the CRC. Third, the presence of carcinoid tumour in the brother of
the MSI R16H-positive patient seems interesting; carcinoids are
neuroendocrine tumours, which often occur as part of complex
familial endocrine cancer syndromes, such as Multiple Endocrine
Neoplasia Type 1 (Leotlela et al, 2003); however, no material was
available for segregation studies of the R16H change in this family.
Aryl hydrocarbon receptor interacting protein analyses in addi-
tional CRC cases and healthy controls would shed light on this
possibility, and clarify whether or not R16H is associated with
neoplasia. We have subsequently encountered the R16H variant in
multiple other individuals with endocrine tumours, but also in one
healthy control (unpublished observations). Thus, it is too early to
conclude whether this change is pathogenic or not.
We next wanted to examine the possibility that AIP is
somatically mutated in unselected breast cancers. Among the
breast tumours analysed, we found no pathogenic changes, but
only silent, previously unreported, polymorphisms. We presume
that the presence of the 30 UTR þ60bp G4C change in a subset of
breast tumour samples, as well as in the two MSI CRC samples, is
incidental. The individuals with the variation were somewhat,
but not significantly, younger at diagnosis than those without the
230 240
230 270 240
Tumour Normal
Wild type
A
B C
Figure 1 Aryl hydrocarbon receptor interacting protein germline change R16H found in two CRC samples. Here, the MSS sample is depicted as example.
(A) Exon 1 wild-type sequence, shown for comparison. (B) R16H detected in the tumour sample. (C) R16H detected in the respective normal sample.
Loss-of-heterozygosity was not observed in either of the cases with the R16H variant. The mutated base 47G4A is indicated by an arrow.
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t-test). The clinical data of the six individuals having the 30
UTRþ60bp G4C change are not uniform: two were familial, one
being BRCA1 mutation-positive (4216nt-2A4G), and the second
being BRCA1/2 mutation-negative. All six breast tumours were
unilateral; five were infiltrating ductal carcinomas, whereas the
familial BRCA1/2 mutation-negative was of medullary type. The
malignancy status was also heterogeneous: two were of advanced
and two of intermediate malignancy, but no information was
available for the remaining two samples. These breast cancer
patients originate from the Oulu region of Northern Finland and
the 30 UTRþ60bp G4C change might represent a variation that is
enriched in this population, as it was also observed in three healthy
controls. We thus assume that the 30 UTRþ60bp G4C change is a
previously unreported polymorphism.
No pathogenic changes were identified in the series of prostate
tumour samples; two silent variants in AIP exons 1 and 5,
respectively, were detected and are likely to be polymorphisms.
These findings suggest that AIP mutations are not common in
breast and prostate cancers.
Despite the high success rate of AIP DNA amplification (99%)
and the sensitivity of our sequencing analysis system, we might
have failed to detect some changes that escape detection by
conventional polymerase chain reaction (PCR) and direct genomic
sequencing. Such changes might include large genomic rearrange-
ments or promoter methylation, which are common mechanisms
for tumour suppressor gene inactivation. On the other hand, our
results are consistent with the fact that some genes mutated in
certain hereditary tumour syndromes are rarely somatically
mutated in sporadic tumours. For instance, BRCA1/2 are the two
major breast and ovarian cancer susceptibility genes. However,
somatic mutations of BRCA1/2 in sporadic breast tumours, as well
as in other cancer types, are very rare (Futreal et al, 1994; Khoo
et al, 1999; Naderi and Couch, 2002; Yang et al, 2002).
The mechanisms by which AIP participates in tumorigenic
events in the pituitary are unknown. The present study does not
provide strong evidence for immediate involvement of AIP in the
initiation or progression of colorectal, breast, and prostate cancer.
It remains to be examined whether AIP is somatically mutated in
other tumour types more related to pituitary adenomas, such as
various neuroendocrine tumours.
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